<DOC>
	<DOCNO>NCT01392547</DOCNO>
	<brief_summary>This trial conduct globally . The purpose trial confirm efficacy safety NNC 0078-0000-0007 patient congenital haemophilia inhibitor .</brief_summary>
	<brief_title>Efficacy Safety NNC 0078-0000-0007 Patients With Congenital Haemophilia Inhibitors</brief_title>
	<detailed_description>Scheduled dose visit non-bleeding state . Single dose NNC 0078-0000-0007 ( vatreptocog alfa ( activate ) ) every 3 month .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Male patient clinical diagnosis congenital haemophilia A B inhibitor coagulation factor VIII IX Minimum five bleeds require haemostatic drug treatment within previous 12 month trial entry Previous participation trial define withdrawal administration trial product Patient receive investigational medicinal product within 30 day prior trial Congenital acquire coagulation disorder haemophilia A B Any clinical sign know history arterial thrombotic event deep venous thrombosis pulmonary embolism ( define available medical record ) Platelet count le 50,000 platelets/mcL ( screen visit ) ALAT ( alaninetransaminase ) 3 time upper normal limit ( accord laboratory reference range ) Factor VIII/IX Immune Tolerance Induction regimen plan occur trial Ongoing bleed prophylaxis regimen plan bleed prophylaxis occur trial HIV ( Human Immunodeficiency Virus ) positive current CD4+ count le 200/mcL ( define medical record )</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>